Abstract
Embryonic stem cells (ESCs) are derived from inner cell mass (ICM) and have the potency to differentiate into three germ layers (ectoderm, endoderm, and mesoderm). This potency of ESCs, called pluripotency, is critical for maintaining stemness. Transcriptional regulatory circuitry preserving stemness consists of transcription factors (TFs), epigenetic mechanisms, microRNAs (miRNAs or miRs), and long non-coding RNAs (lncRNAs). In this circuitry, components assist each other to activate essential genes for maintaining pluripotency and suppressing lineage-specific genes. TFs act directly by binding to their binding sites in the genome or indirectly by activating another gene (such as a miR), epigenetic mechanisms play their role by providing an activatory or inhibitory context for transcription, miRNAs regulate gene expression at the post-transcriptional level, and lncRNAs act as a scaffold function for epigenetic elements, regulating gene expression in ESCs. All these factors create a crossroad and collaborate to sustain stemness in the ESCs. Herein, we explain the role of each member in this circuitry and demonstrate the significance of the crossroad for keeping stemness.
Keywords: ESCs, pluripotency, self-renewal, core transcriptional regulatory circuitry.
Current Stem Cell Research & Therapy
Title:Pluripotency Crossroads: Junction of Transcription Factors, Epigenetic Mechanisms, MicroRNAs, and Long Non-coding RNAs
Volume: 12 Issue: 4
Author(s): Seyed M.A.H. Rad, Abdollah Mohammadi-Sangcheshmeh, Taravat Bamdad, Lida Langroudi, Amir Atashi, Majid Lotfinia, Ehsan Arefian, Eduardo L. Gastal and Masoud Soleimani
Affiliation:
Keywords: ESCs, pluripotency, self-renewal, core transcriptional regulatory circuitry.
Abstract: Embryonic stem cells (ESCs) are derived from inner cell mass (ICM) and have the potency to differentiate into three germ layers (ectoderm, endoderm, and mesoderm). This potency of ESCs, called pluripotency, is critical for maintaining stemness. Transcriptional regulatory circuitry preserving stemness consists of transcription factors (TFs), epigenetic mechanisms, microRNAs (miRNAs or miRs), and long non-coding RNAs (lncRNAs). In this circuitry, components assist each other to activate essential genes for maintaining pluripotency and suppressing lineage-specific genes. TFs act directly by binding to their binding sites in the genome or indirectly by activating another gene (such as a miR), epigenetic mechanisms play their role by providing an activatory or inhibitory context for transcription, miRNAs regulate gene expression at the post-transcriptional level, and lncRNAs act as a scaffold function for epigenetic elements, regulating gene expression in ESCs. All these factors create a crossroad and collaborate to sustain stemness in the ESCs. Herein, we explain the role of each member in this circuitry and demonstrate the significance of the crossroad for keeping stemness.
Export Options
About this article
Cite this article as:
Rad M.A.H. Seyed, Mohammadi-Sangcheshmeh Abdollah, Bamdad Taravat, Langroudi Lida, Atashi Amir, Lotfinia Majid, Arefian Ehsan, Gastal L. Eduardo and Soleimani Masoud, Pluripotency Crossroads: Junction of Transcription Factors, Epigenetic Mechanisms, MicroRNAs, and Long Non-coding RNAs, Current Stem Cell Research & Therapy 2017; 12 (4) . https://dx.doi.org/10.2174/1574888X12666170216155850
DOI https://dx.doi.org/10.2174/1574888X12666170216155850 |
Print ISSN 1574-888X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3946 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Dine (Damage-Induced Neuronal Endopeptidase)
Protein & Peptide Letters The Role of T-Type Calcium Channels in Peripheral and Central Pain Processing
CNS & Neurological Disorders - Drug Targets Nanotechnology as an Adjunct Tool for Transplanting Engineered Cells and Tissues
Current Molecular Medicine Adrenomedullin: Exciting New Horizons
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery The Surgical Management of Parkinson's Disease
CNS & Neurological Disorders - Drug Targets PD-1/PD-Ls: A New Target for Regulating Immunopathogenesis in Central Nervous System Disorders
Current Drug Delivery Nanotechnology and Antioxidant Therapy: An Emerging Approach for Neurodegenerative Diseases
Current Medicinal Chemistry Immunophilins: Structures, Mechanisms and Ligands
Current Molecular Pharmacology Neurotoxicity and Side-Effects of Highly Active Antiretroviral Therapy [HAART] on the Central and Peripheral Nerve System
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Proteomic Comparison of Damaged Sciatic Nerves of a Newt, Triturus <i>karelinii</i> (Amphibia: Urodela) During the First 24<sup>th</sup> Hour of Regeneration Period
Current Proteomics Inflammation Fueling Atrial Fibrillation Substrate: Seeking Ways to "Cool" the Heart
Medicinal Chemistry Parkinson’s Disease: Is there a Role for Dietary and Herbal Supplements?
CNS & Neurological Disorders - Drug Targets Administration of Autologous Mesenchymal Cells for the Treatment of Arthritis
Current Stem Cell Research & Therapy Plasmid DNA-based Gene Transfer with Ultrasound and Microbubbles
Current Gene Therapy Regulatory T Cells in Central Nervous System: in Health and Disease
Central Nervous System Agents in Medicinal Chemistry PET Imaging of the Peripheral Benzodiazepine Receptor: Monitoring Disease Progression and Therapy Response in Neurodegenerative Disorders
Current Pharmaceutical Design Neural Plasticity After Spinal Cord Injury
Current Pharmaceutical Design Regenerative Medicine for Spinal Cord Injury
Recent Patents on Regenerative Medicine Involvement of Immune Response in the Pathogenesis of Amyotrophic Lateral Sclerosis: A Therapeutic Opportunity?
CNS & Neurological Disorders - Drug Targets Glycogen Synthase Kinase-3 (GSK-3) Inhibitors for the Treatment of Alzheimers Disease
Current Pharmaceutical Design